XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

Bayer earnings hit by tough farm market in fresh challenge for CEO



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Bayer earnings hit by tough farm market in fresh challenge for CEO</title></head><body>

Adds details and CEO quote on overhaul from paragraph 6

By Ludwig Burger

FRANKFURT, Aug 6 (Reuters) -Bayer BAYGn.DE posted a 16.5% drop in quarterly adjusted earnings on Tuesday, becoming the latest agricultural chemicals supplier to be hit by weak demand due to lower grains prices and adding to the CEO's challenges in his second year in the job.

Bayer boss Bill Anderson has launched a push to speed up decision making and slash corporate bureaucracy to turn around the embattled industrial group, and job cuts gathered pace in the second quarter, according to the group's statement.

The group's April-to-June earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, fell to 2.1 billion euros ($2.3 billion), also dragged lower by negative foreign exchange effects, in line with an average analyst estimate posted on the company's website.

Bayer, which had close to 100,000 staff at the end of 2023, said it had cut the equivalent of 3,200 full-time jobs during the first six months of this year, marking an acceleration after cutting 1,500 jobs during the first quarter.

The CEO, who is slashing hierarchy levels to give product developers and sales people more power, has ruled out any staff reduction targets beyond saying cuts would be significant.

The voluntary redundancies, affecting managers primarily, have so far been consistent with a target to cut 2 billion euros in annual costs from 2026, Anderson said.

"This is exactly what we envisioned," he told a media call.


TOUGH FARMING MARKET

The tough farming market has been felt by rivals including Corteva CTVA.N of the United States, which last week cut full-year forecasts, hurt by lower prices.

A decline in agricultural commodity prices has forced many farmers to rein in their spending on crop chemicals.

BASF, another major competitor, has said herbicide and fungicide sale volumes declined during the April-to-June quarter, normally a key earnings-generating season for the industry.

Bayer confirmed its previous full-year earnings guidance, saying agriculture product margins would recover, excluding earnings from the glyphosate weedkiller, which has been subject to costly legal claims alleging that it causes cancer.

The company's shares were little changed at 0908 GMT, with Deutsche Bank analysts saying in a research note that better-than-expected pharmaceutical sales were broadly offset by a disappointing agriculture business.

Anderson said in March he would hold off for up to three years on previous preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.

His focus is instead on changing Bayer's management structure as well as on cutting debt and dealing with a massive wave of U.S. product liability lawsuits even though the U.S. environmental regulator has declared glyphosate safe to use.

Anderson, who became CEO in June 2023, has had a tumultuous start in the job marked by falling share prices and efforts to end the glyphosate litigation. The group also suffered a major setback in drug development late last year.

The CEO, however, clearly won a confidence vote at his first annual general meeting for Bayer in April. Earlier in the year, top-five shareholder Harris Associates came out in strong support for the CEO's course.



Reporting by Ludwig Burger;
Editing by Rachel More and Helen Popper

</body></html>

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.